Company news

Agenus Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting

April 23, 2024

Agenus to Provide First Quarter 2024 Financial Report and Corporate Update

April 22, 2024

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

April 11, 2024

Agenus Announces Reverse Stock Split of Common Stock

April 4, 2024

Agenus Reports Fourth Quarter and Full Year 2023 Results

March 13, 2024

Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

March 5, 2024

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

February 28, 2024

Agenus to Participate in Leerink Partners Global Biopharma Conference

February 25, 2024

Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design

February 14, 2024

Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 30, 2024

Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population

January 21, 2024

Agenus to Participate in B. Riley Healthcare Conference

January 3, 2024

Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024

December 19, 2023

Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program

December 10, 2023

Agenus Reports Third Quarter 2023 Results

November 6, 2023

Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update

October 25, 2023

Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

October 21, 2023

ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes

October 20, 2023

Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer

October 9, 2023

Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

August 22, 2023

Agenus Reports Second Quarter 2023 Results

August 7, 2023

Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update

July 25, 2023

Agenus Expands Executive Leadership Team

July 19, 2023

Agenus Provides Corporate Update and First Quarter 2023 Financial Results

May 8, 2023

Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer

April 16, 2023

Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics

March 29, 2023

Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives

March 13, 2023

Agenus Provides Corporate Update and Third Quarter 2022 Financial Report

November 7, 2022

Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report

October 24, 2022

Agenus Makes Senior Regulatory and Clinical Appointments

September 11, 2022

Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma

September 11, 2022

Agenus Provides Corporate Update and Second Quarter 2022 Financial Report

August 8, 2022

Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors

July 31, 2022

Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report

July 26, 2022

Agenus Advances Portfolio with 6 Clinical Collaborations

May 30, 2022

Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance Botensilimab

May 23, 2022

Agenus Corporate Update and First Quarter 2022 Financial Report

May 9, 2022

Agenus to Provide Corporate Update and First Quarter 2022 Financial Report

April 25, 2022

Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance

April 7, 2022

Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report

February 28, 2022

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2021 Financial Report

February 14, 2022

Agenus Corporate Update and Third Quarter 2021 Financial Report

November 8, 2021

Agenus to Provide Corporate Update and Third Quarter 2021 Financial Report

October 24, 2021

Agenus Provides Update on Balstilimab Development

October 21, 2021

Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody

October 11, 2021

Agenus Corporate Update and Second Quarter 2021 Financial Report

August 8, 2021

Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report

July 25, 2021

Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777

July 5, 2021

Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer

June 16, 2021

Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program

May 17, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 26 decks. Every deck is listed under its year.